167 related articles for article (PubMed ID: 33892220)
1. Progressive multifocal leukoencephalopathy in an elderly immunocompetent-appearing patient: Relevance with L-selectin (CD62L) expression and immunosenescence.
Boziki M; Metallidis S; Habidou E; Afrantou T; Bakirtzis C; Cheva A; Finitsis S; Grigoriadis N
Clin Neurol Neurosurg; 2021 Jun; 205():106625. PubMed ID: 33892220
[TBL] [Abstract][Full Text] [Related]
2. PML risk stratification using anti-JCV antibody index and L-selectin.
Schwab N; Schneider-Hohendorf T; Pignolet B; Spadaro M; Görlich D; Meinl I; Windhagen S; Tackenberg B; Breuer J; Cantó E; Kümpfel T; Hohlfeld R; Siffrin V; Luessi F; Posevitz-Fejfár A; Montalban X; Meuth SG; Zipp F; Gold R; Du Pasquier RA; Kleinschnitz C; Jacobi A; Comabella M; Bertolotto A; Brassat D; Wiendl H
Mult Scler; 2016 Jul; 22(8):1048-60. PubMed ID: 26432858
[TBL] [Abstract][Full Text] [Related]
3. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk.
Boziki MK; Karapanayotides T; Papadopoulos G; Lagoudaki R; Melo P; Bakirtzis C; Nikolaidis I; Gounari E; Tsavdaridou V; Skoura L; Afrantou T; Tatsi T; Grigoriadou E; Polyzoidou E; Mandoras N; Giantzi V; Kalogera-Fountzila A; Ioannidis P; Parissis D; Pelidou SH; Zoidou S; Grigoriadis N
Neurol Res; 2020 Mar; 42(3):209-221. PubMed ID: 32048570
[No Abstract] [Full Text] [Related]
5. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
[TBL] [Abstract][Full Text] [Related]
6. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A
Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785
[TBL] [Abstract][Full Text] [Related]
7. The spectrum of progressive multifocal leukoencephalopathy: a practical approach.
Bartsch T; Rempe T; Leypoldt F; Riedel C; Jansen O; Berg D; Deuschl G
Eur J Neurol; 2019 Apr; 26(4):566-e41. PubMed ID: 30629326
[TBL] [Abstract][Full Text] [Related]
8. Progressive multifocal leukoencephalopathy with a benign prognosis in an immunocompetent patient - A case report.
Zeynep Ö; Serap TR; Burcu Y; Aysun S
Ideggyogy Sz; 2024 Jan; 77(1-2):60-64. PubMed ID: 38321853
[TBL] [Abstract][Full Text] [Related]
9. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.
Lieberman LA; Zeng W; Singh C; Wang W; Otipoby KL; Loh C; Plavina T; Gorelik L; Ransohoff RM; Cahir-McFarland E
Neurology; 2016 Jan; 86(4):375-81. PubMed ID: 26718566
[TBL] [Abstract][Full Text] [Related]
10. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Plavina T; Subramanyam M; Bloomgren G; Richman S; Pace A; Lee S; Schlain B; Campagnolo D; Belachew S; Ticho B
Ann Neurol; 2014 Dec; 76(6):802-12. PubMed ID: 25273271
[TBL] [Abstract][Full Text] [Related]
11. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.
Schwab N; Schneider-Hohendorf T; Wiendl H
Neurology; 2016 Aug; 87(9):958-9. PubMed ID: 27572431
[No Abstract] [Full Text] [Related]
12. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.
Piu C; Ibba G; Bertoli D; Capra R; Uleri E; Serra C; Imberti L; Dolei A
J Neurovirol; 2020 Feb; 26(1):133-137. PubMed ID: 31468472
[TBL] [Abstract][Full Text] [Related]
13. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
14. Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression.
Grewal J; Dalal P; Bowman M; Kaya B; Otero JJ; Imitola J
J Neurovirol; 2016 Oct; 22(5):683-687. PubMed ID: 27273076
[TBL] [Abstract][Full Text] [Related]
15. Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.
Schwab N; Schneider-Hohendorf T; Pignolet B; Bucciarelli F; Scandella L; Ciron J; Biotti D; Lebrun-Frenay C; Mathey G; Clavelou P; Pelletier J; Ostkamp P; Meinl I; Windhagen S; Klotz L; Gross CC; Meuth SG; Deisenhammer F; Brassat D; Wiendl H;
Neurology; 2019 Sep; 93(12):550-554. PubMed ID: 31439633
[No Abstract] [Full Text] [Related]
16. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
Perkins MR; Ryschkewitsch C; Liebner JC; Monaco MC; Himelfarb D; Ireland S; Roque A; Edward HL; Jensen PN; Remington G; Abraham T; Abraham J; Greenberg B; Kaufman C; LaGanke C; Monson NL; Xu X; Frohman E; Major EO; Douek DC
PLoS Pathog; 2012; 8(11):e1003014. PubMed ID: 23144619
[TBL] [Abstract][Full Text] [Related]
17. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
[TBL] [Abstract][Full Text] [Related]
18. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J
Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.
Iannetta M; Zingaropoli MA; Bellizzi A; Morreale M; Pontecorvo S; D'Abramo A; Oliva A; Anzivino E; Lo Menzo S; D'Agostino C; Mastroianni CM; Millefiorini E; Pietropaolo V; Francia A; Vullo V; Ciardi MR
PLoS One; 2016; 11(8):e0160277. PubMed ID: 27486658
[TBL] [Abstract][Full Text] [Related]
20. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
